FDA approves diabetes drug that also helps with weight loss

  • Dec. 5, 2017 2:26 p.m.

TRENTON, N.J. — U.S. regulators on Tuesday approved a new diabetes drug that reduces blood sugar levels and also helps people lose significant weight.

Danish drugmaker Novo Nordisk said the Food and Drug Administration approved its once-a-week shot for people with Type 2 diabetes. The drug, Ozempic, also known as semaglutide, works by stimulating the body’s own insulin production and reducing appetite.

In one big company-funded study, Ozempic, on average, reduced long-term blood sugar levels at least 2 1/2 times as much as a popular daily diabetes pill, Merck & Co.’s Januvia. It also helped study participants lose two to three times as much weight as those in the comparison group.

Over 56 weeks, patients who got a lower dose of Ozempic lost an average of 9.5 pounds (4.3 kilograms) while those who got a higher dose lost 13.5 pounds (6.1 kilograms). The patients who took Januvia lost an average of 4 pounds (1.9 kilograms).

The 1,200 study participants were also taking one or two standard diabetes medicines.

Novo Nordisk, a leader in diabetes care, has also been testing the drug separately for weight loss alone.

Many Type 2 diabetes patients are overweight or obese, and losing significant weight usually helps them reduce their blood sugar and better control their diabetes. Over time, too high sugar in the blood can damage multiple organs and weaken circulation.

The new drug comes in injector pens and costs about the same as similar weekly drugs: $676 for a four- to six-week supply without insurance. Novo Nordisk already sells a similar once-a-day shot, Victoza.

Ozempic will compete with other popular once-a-week drugs in the same class, including Eli Lilly and Co.’s Trulicity and AstraZeneca PLC’s Bydureon, which don’t produce as much weight loss. However, they all carry warnings about possible serious side effects, including kidney damage and inflammation of the pancreas. They also may be linked to thyroid cancer, so people taking all drugs in the class are being followed via a patient registry.

Januvia is in a different drug class.

Just Posted

Coat, cash donations accepted on the side of the road in Red Deer

Fifth annual Coats for Kids and CACPC Charity Checkstop held Saturday afternoon on Taylor Drive

UPDATE: Red Deer RCMP locate missing 64-year-old woman

Red Deer RCMP have located a 64-year-old woman, who was reported missing,… Continue reading

Not a political question: Thunberg calls for climate action in Alberta

EDMONTON — Teen climate activist Greta Thunberg marched into the middle of… Continue reading

Alleged sex assault victim details struggles in proposed suit against Toronto school

TORONTO — A former student at an all-boys Catholic school in Toronto… Continue reading

WATCH: Red Deer Citizens on Patrol monitoring downtown with new program

Volunteers will patrol downtown Red Deer to help keep the city safe.… Continue reading

Your community calendar

Tuesday The Small Business Centre at Burman University’s School of Business invites… Continue reading

Scheer won’t say if Conservatives hired consultant to ‘destroy’ People’s party

TORONTO — With election day less than 48 hours away, Andrew Scheer… Continue reading

Man’s death in Richmond, B.C. suspicious, not random, say investigators

RICHMOND, B.C. — The discovery of a man’s body in a Richmond,… Continue reading

Quebec man found guilty of first-degree murder in slaying of ex-wife, stranger

ST-JEROME, Que. — A Quebec man was found guilty of first-degree murder… Continue reading

Mexico says Trump shows ‘solidarity’ after suspect freed

MEXICO CITY — Mexican President Andrés Manuel López Obrador said Saturday he… Continue reading

‘I am back,’ Bernie Sanders tells supporters at NYC rally

NEW YORK — Storming past questions about his health, Bernie Sanders vowed… Continue reading

Leaders pour it on with rallies, boosts for candidates as campaign reaches peak

OTTAWA — Liberal Leader Justin Trudeau has a marathon day of campaigning… Continue reading

Most Read